Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle

Virology

Volumn 386, Issue 2, 2009, Pages 438-447

  Yue, Yan ^a   Xu, Wei ^a   Hu, Linkun ^a   Jiang, Zhenggang ^a   Xiong, Sidong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chitosan; Coxsackievirus B3; Lymphotactin; Mucosal immune response; Viral myocarditis

Indexed keywords

CHITOSAN; LYMPHOTACTIN;

ANIMAL EXPERIMENT; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; COXSACKIE VIRUS B3; IMMUNE RESPONSE; IMMUNIZATION; INTESTINE MUCOSA; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CHITOSAN; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNIZATION; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; NEUTRALIZATION TESTS; SIALOGLYCOPROTEINS; TH1 CELLS; VACCINES, DNA; VIRAL LOAD; VIRAL VACCINES;

COXSACKIEVIRUS; MUS;

EID: 62749102116     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.01.029     Document Type: Article

References (35)

1. Amin P.B., Diebel L.N., and Liberati D.M. T-cell cytokines affect mucosal immunoglobulin A transport. Am. J. Surg. 194 1 (2007) 128-133
2. Avery D.T., Bryant V.L., Ma C.S., de Waal Malefyt R., and Tangye S.G. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J. Immunol. 181 3 (2008) 1767-1779
3. Bailey J.M., and Tapprich W.E. Structure of the 5′ nontranslated region of the coxsackievirus b3 genome: chemical modification and comparative sequence analysis. J. Virol. 81 2 (2007) 650-668
4. + T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals. J. Immunol. 181 3 (2008) 2111-2123
5. Boismenu R., Feng L., Xia Y.Y., Chang J.C., and Havran W.L. Chemokine expression by intraepithelial γδ T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J. Immunol. 157 3 (1996) 985-992
6. Capozzo A.V., Ramirez K., Polo J.M., Ulmer J., Barry E.M., Levine M.M., and Pasetti M.F. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J. Immunol. 176 9 (2006) 5671-5681
7. Dass C.R., and Choong P.F. Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy. J. Drug Target. 16 4 (2008) 257-261
8. Dorner B.G., Scheffold A., Rolph M.S., Huser M.B., Kaufmann S.H., Radbruch A., Flesch I.E., and Kroczek R.A. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc. Natl. Acad. Sci. U. S. A. 99 9 (2002) 6181-6186
9. Fagarasan S. Evolution, development, mechanism and function of IgA in the gut. Curr. Opin. Immunol. 20 2 (2008) 170-177
10. Fairweather D., Frisancho-Kiss S., Yusung S.A., Barrett M.A., Davis S.E., Steele R.A., Gatewood S.J., and Rose N.R. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-γ and macrophage and neutrophil populations in the heart. J. Immunol. 174 1 (2005) 261-269
11. Feng X.J., Wang J.H., Shan A.S., Teng D., Yang Y.L., Yao Y., Yang G.P., Shao Y.C., Liu S., and Zhang F. Fusion expression of bovine lactoferricin in Escherichia coli. Protein Expr. Purif. 47 1 (2006) 110-117
12. Haarmann C.M., Schwimmbeck P.L., Mertens T., Schultheiss H.P., and Strauer B.E. Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides. Virology 200 2 (1994) 381-389
13. Hasegawa H., Ichinohe T., Tamura S., and Kurata T. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert. Rev. Vaccines 6 2 (2007) 193-201
14. Henke A., Jarasch N., Martin U., Wegert J., Wildner A., Zell R., and Wutzler P. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int. J. Med. Microbiol. 298 1-2 (2008) 127-134
15. + cells. Microbes Infect. 7 3 (2005) 537-543
16. Ichinohe T., Tamura S., Kawaguchi A., Ninomiya A., Imai M., Itamura S., Odagiri T., Tashiro M., Takahashi H., Sawa H., Mitchell W.M., Strayer D.R., Carter W.A., Chiba J., Kurata T., Sata T., and Hasegawa H. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 196 9 (2007) 1313-1320
17. Ivory C.P., and Chadee K. Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge. Infect. Immun. 75 10 (2007) 4917-4922
18. Jiang L., Qian F., He X., Wang F., Ren D., He Y., Li K., Sun S., and Yin C. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. J. Gene Med. 9 4 (2007) 253-264
19. Ju D.W., Tao Q., Cheng D.S., Zhang W., Zhang M., Hamada H., and Cao X. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther. 7 4 (2000) 329-338
20. + dendritic cells for enhanced mucosal immunity. J. Immunol. 172 6 (2004) 3612-3619
21. Kim J.Y., Jeon E.S., Lim B.K., Kim S.M., Chung S.K., Kim J.M., Park S.I., Jo I., and Nam J.H. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 23 14 (2005) 1672-1679
22. Lillard Jr. J.W., Boyaka P.N., Hedrick J.A., Zlotnik A., and McGhee J.R. Lymphotactin acts as an innate mucosal adjuvant. J. Immunol. 162 4 (1999) 1959-1965
23. Mantovani A., Bonecchi R., and Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 6 12 (2006) 907-918
24. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6 2 (2006) 148-158
25. (+) regulatory T cells. Cell Death Differ. 14 12 (2007) 2076-2084
26. Roy K., Mao H.Q., Huang S.K., and Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5 4 (1999) 387-391
27. + T cells during picornavirus infection. J. Virol. 75 5 (2001) 2377-2387
28. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., Czerkinsky C., and Kweon M.N. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl. Acad. Sci. U. S. A. 105 5 (2008) 1644-1649
29. Tam P.E. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 19 2 (2006) 133-146
30. Toka F.N., Gierynska M., and Rouse B.T. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J. Virol. 77 23 (2003) 12742-12752
31. Vasir J.K., and Labhasetwar V. Polymeric nanoparticles for gene delivery. Expert. Opin. Drug Deliv. 3 3 (2006) 325-344
32. Wang X., Zhang X., Kang Y., Jin H., Du X., Zhao G., Yu Y., Li J., Su B., Huang C., and Wang B. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 26 40 (2008) 5135-5144
33. Xu W., Shen Y., Jiang Z., Wang Y., Chu Y., and Xiong S. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22 27-28 (2004) 3603-3612
34. Yang X., Fan Y., Wang S., Han X., Yang J., Bilenki L., and Chen L. Mycobacterial infection inhibits established allergic inflammatory responses via alteration of cytokine production and vascular cell adhesion molecule-1 expression. Immunology 105 3 (2002) 336-343
35. Zuercher A.W., Jiang H.Q., Thurnheer M.C., Cuff C.F., and Cebra J.J. Distinct mechanisms for cross-protection of the upper versus lower respiratory tract through intestinal priming. J. Immunol. 169 7 (2002) 3920-3925